IRRAflow® Advantages

Enhanced Drainage

Current drainage systems, such as external ventricular drains (EVDs), are vital tools in managing a patient’s ICP during neurocritical care situations. By draining excess fluid, an EVD plays a critical role in stabilizing the intracranial pressure (ICP) of these critically ill patients, which can facilitate recovery. Unfortunately, EVDs are generally primitive systems that rely solely on gravity alone, and as a result, they have been plagued by blockages that can lead to inefficient drainage and other complications.

IRRAflow addresses this inefficient drainage by returning control of the drainage process to the clinician.  This is accomplished with a therapeutic treatment called active fluid exchange.  Active fluid exchange, by design, cleans the entire catheter probe’s inner surface while the fluid movement helps to disrupt potential clot or bacteria colony formation on the catheter probe’s intracranial external surface, thereby eliminating the underlying reasons for the problems associated with passive drainage: blockage and infection.

Integrated, Continuous ICP Monitoring

Elevated intracranial pressure (ICP) is a common cause of neurological damage and death in patients with any neurosurgical disorder. Continuous ICP monitoring has been clinically proven in studies since 2012 to decrease patient mortality rates.1 Given this, it is vital that you have a product that not only has continuous monitoring, but also has a drainage catheter that remains unobstructed during the procedure.

IRRAflow provides these attributes by combining drainage, irrigation, and pressure monitoring into one easy-to-use integrated fluid management system. This innovative, new monitoring system automates pressure data collection, allows for custom alarms when pressure rises, and actively manages ICP through its proprietary fluid exchange technology.

1. Yuan Q, Wu X, Sun Y, et al. Impact of intracranial pressure monitoring on mortality in patients with traumatic brain injury: a systematic review and meta-analysis. J Neurosurg. 2015;122:574–87.

Potential to Reduce Occlusions & Infections

The evolution of EVD technology has been limited, so neurosurgeons and ICU staff still deal with catheter occlusion rates up to 40%1 as well as infection rates that can range from 2 – 24%.2 At IRRAS, we believe that it is time for a needed step forward in fluid management technology that addresses these clinical challenges and improves outcomes.

Irrigation-Aspiration2

IRRAflow’s innovative closed system design responds to these issues with its use of a proprietary dual-lumen catheter and automated software to drain excess fluid in a controlled fashion. On a regular basis, IRRAflow provides an irrigation pulse to flush the catheter, which keeps the holes in the catheter tip unobstructed and prevents catheter blockages from forming. By doing so, IRRAflow eliminates the need for nursing staff to manually inject fluids to keep the catheter open and also reduces the likelihood that the drainage catheter will have to be replaced to allow drainage to continue. By reducing these possibilities, IRRAflow’s completely closed system removes opportunities for outside pathogens to be introduced, which can thereby reduce the chance of infection for the patient.

1. Fargen KM, Hoh BL, Neal D, O’Connor T, Rivera-Zengotita M, Murad GJ. The burden and risk factors of ventriculostomy occlusion in a high-volume cerebrovascular practice: results of an ongoing prospective database. Journal of Neurosurgery. 2015:1-8.
2. Citerio G, Signorini L, Bronco A, Vargiolu A, Rota M, Latronico N. External Ventricular and Lumbar Drain Device Infections in ICU Patients: A Prospective Multicenter Italian Study. Crit Care Med. 2015 Aug;43(8):1630-7.

Designed with Cost Effectiveness in Mind

The IRRAflow system is a long overdue step forward in the management of intracerebral fluids and ICP in neuro ICU patients. It has been designed to address the shortcomings of existing technologies and provides an intelligent, next-generation solution.

These advancements are important due to the fact that increased complications and incomplete drainage can extend ICU time for patients, which results in added costs for patients and the hospital. With actively controlled drainage and a potential reduction in catheter blockages and associated complications, IRRAflow is designed to help patients recover faster. In early clinical experience with the system, in a collection of 32 subdural hematoma patients treated,1 IRRAflow showed positive clinical outcomes with shorter treatment timelines than conventional treatment methods, which resulted in estimated cost savings of between EUR 4,300 and EUR 7,700 per patient.1

 

Economic-Benefits
Treatment with IRRAflow may result in significant health economic benefits
ICU-Chart
Significant savings from shorter ICU
and ward stays1
Treatment-Representation
Treatment overview of representative clinical cases from Germany in 20171

1. Data on File. Treatment outcome with IRRAflow based on 32 subdural cases at early Germany experience sites as of August 15, 2017, compared to hospital’s historic length of stay.